ICU Medical (NASDAQ:ICUI) Reaches New 1-Year High at $181.16

ICU Medical, Inc. (NASDAQ:ICUI)’s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $181.16 and last traded at $181.16, with a volume of 12675 shares traded. The stock had previously closed at $179.00.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ICUI shares. KeyCorp boosted their target price on shares of ICU Medical from $136.00 to $147.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a report on Thursday, August 8th. Finally, Raymond James upped their price target on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, ICU Medical presently has an average rating of “Moderate Buy” and an average price target of $149.00.

ICU Medical Stock Performance

The company’s 50-day moving average price is $146.75 and its two-hundred day moving average price is $120.07. The company has a market capitalization of $4.29 billion, a price-to-earnings ratio of -72.27 and a beta of 0.65. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 1.08.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.56. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The business had revenue of $596.50 million for the quarter, compared to analysts’ expectations of $556.64 million. During the same quarter in the prior year, the firm posted $1.58 earnings per share. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. On average, equities research analysts anticipate that ICU Medical, Inc. will post 3.76 EPS for the current fiscal year.

Insider Buying and Selling

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total value of $1,961,520.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at $17,096,771.78. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, VP Virginia Ruth Sanzone sold 2,050 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $144.11, for a total transaction of $295,425.50. Following the transaction, the vice president now owns 4,482 shares in the company, valued at $645,901.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total value of $1,961,520.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $17,096,771.78. The disclosure for this sale can be found here. Insiders sold 28,552 shares of company stock valued at $4,537,802 over the last 90 days. Company insiders own 6.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its holdings in shares of ICU Medical by 14.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 192,773 shares of the medical instruments supplier’s stock valued at $19,227,000 after acquiring an additional 23,816 shares in the last quarter. Jump Financial LLC bought a new position in shares of ICU Medical in the 4th quarter worth $352,000. Dimensional Fund Advisors LP grew its position in ICU Medical by 4.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 220,624 shares of the medical instruments supplier’s stock valued at $22,005,000 after purchasing an additional 9,196 shares during the period. Principal Financial Group Inc. increased its stake in ICU Medical by 37.8% during the 4th quarter. Principal Financial Group Inc. now owns 107,335 shares of the medical instruments supplier’s stock valued at $10,706,000 after purchasing an additional 29,464 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in ICU Medical during the fourth quarter worth $351,000. 96.10% of the stock is owned by institutional investors and hedge funds.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.